Ascendis Pharma A/S announced its financial results for the fourth quarter and full year ended December 31, 2024. Total revenue for Q4 2024 reached €173.9 million, an increase from €137.7 million in the same period of 2023, while full year 2024 total revenue was €363.6 million, up from €266.7 million in 2023.
The revenue increase was primarily attributable to the $100 million upfront fee from Novo Nordisk and the successful EU launch of YORVIPATH. SKYTROFA generated approximately €202 million in revenue for the full year 2024, excluding sales deductions related to prior years, and YORVIPATH contributed €28.7 million in full year 2024 revenue.
The company reported a strong start to the U.S. YORVIPATH launch, with 908 prescriptions and 539 unique prescribing healthcare providers as of February 7, 2025. Ascendis Pharma's net loss for Q4 2024 was €38.5 million, or €0.64 per share, and for the full year 2024 was €378.1 million, or €6.53 per share. Total operating expenses for 2024 were €598 million, and the company ended the year with €559.5 million in cash, cash equivalents, and marketable securities, with the $100 million Novo Nordisk payment received in January 2025. The company remains on track to submit the TransCon CNP NDA for achondroplasia in Q1 2025 and the MAA in Q3 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.